Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS news (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on SHUTTLE PHARMACTCLS HLDGS stock.
Shuttle Pharmaceuticals Holdings, Inc. develops cancer-therapy programs and drug-development technologies, with a focus on radiotherapy-related treatments and the Molecule.ai platform for molecular discovery and early-stage drug development. Its updates commonly address pipeline and platform development, including Ropidoxuridine, HDAC inhibitors, PSMA-B, PC-Rad Test and AI models for evaluating biological targets and therapeutic candidates.
Company news also includes financing activity, securities offerings, material agreements, shareholder-voting matters, governance updates and operating or financial results. The completed acquisition of Molecule.ai added an artificial-intelligence software asset to Shuttle Pharma's drug-discovery and predictive-analytics capabilities.
Shuttle Pharmaceuticals (NASDAQ:SHPH) closed its merger with United Dogecoin, making United Dogecoin a wholly owned subsidiary. The combined company will focus on mining Dogecoin (DOGE) and Litecoin (LTC) and holding mined coins as long-term treasury assets.
Shuttle issued 8,000 shares of Series B-1 Convertible Preferred Stock, potentially convertible into about 32,264,000 common shares, reserved up to 118,038,551 pre-funded warrants tied to post-closing milestones, and completed a $9.55 million PIPE financing. A purchase order grants the option to buy up to 3,000 ElphaPex Scrypt mining rigs, expected to provide up to roughly 43,200 GH/s and begin coming online within 60 days of equipment receipt.
Shuttle (NASDAQ: SHPH) entered a definitive merger to acquire United Dogecoin and will issue Series B-1 preferred stock to United Dogecoin holders, subject to shareholder approval. A concurrent $11 million PIPE is expected to close May 4, 2026. United Dogecoin plans up to 3,000 ElphaPex rigs delivering up to 43,200 GH/s (~1.5% global Dogecoin hashrate) within 60 days and anticipates low-cost, renewable energy and preferential hardware access.
Shuttle (NASDAQ: SHPH) agreed to acquire United Dogecoin and will merge it into a wholly owned subsidiary, supported by an $11 million PIPE expected to close May 4, 2026. United Dogecoin intends to order up to 3,000 ElphaPex mining rigs for up to 43,200 GH/s (about 1.5% of global Dogecoin hashrate).
Transaction consideration includes 8,000 Series B-1 convertible preferred (≈32,258,064 common shares on conversion) and contingent pre-funded warrants tied to operational milestones; PIPE investors receive Series B-2 securities and warrants convertible upon shareholder approval.
Shuttle Pharmaceuticals (NASDAQ:SHPH) on March 27, 2026 announced a major upgrade to its molecule.ai platform, adding generative and predictive models plus a preview of an autonomous, multi-agent AI system for scientific workflows.
The release emphasizes multi-step reasoning, multimodal data ingestion, and orchestration to accelerate therapeutic discovery and reduce manual research effort.
Shuttle Pharmaceuticals (NASDAQ: SHPH) on March 26, 2026 announced a major expansion of its molecule.ai platform, adding new predictive and generative models and a preview of an autonomous, multi-agent AI system for scientific workflows.
The update enables multi-step reasoning, multimodal data ingestion, and prioritization of gene–disease and compound–target relationships to accelerate early therapeutic discovery and reduce manual research effort.
Shuttle Pharmaceuticals (NASDAQ: SHPH) announced a public offering to issue 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares for aggregate gross proceeds of approximately $3.5 million.
The offering is expected to close on or about March 9, 2026, with E.F. Hutton & Co. as exclusive placement agent. The company intends to use up to $1.5 million for marketing and the remainder for working capital and general corporate purposes. The securities are being offered under an effective Form S-1 (File No. 333-293363) registration statement.
Shuttle Pharmaceuticals (NASDAQ: SHPH) on January 13, 2026 highlighted Utah's new pilot allowing AI to authorize prescription refills and explained why that regulatory milestone matters for its Molecule.ai drug‑discovery platform. The release links Utah's AI refill program to time and cost savings in healthcare and argues Molecule.ai can similarly cut drug discovery bottlenecks by reducing time to identify candidates, lowering failed‑experiment costs, and automating repetitive screening.
The company says Molecule.ai uses agentic AI with uncertainty quantification, human‑in‑the‑loop workflows, and explainable models to enable oversight and scale while aiming to accelerate R&D and improve access to therapies.
Shuttle Pharmaceuticals (NASDAQ: SHPH) announced it closed the acquisition of substantially all assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai for a total purchase price of $8 million payable in cash and Shuttle common stock, plus a contingent $2 million in cash and stock tied to performance milestones.
An initial $3 million was paid at closing; remaining consideration will be delivered over time and, for contingent payments, subject to milestone achievement and Molecule's election of cash or equity. Shuttle said the acquisition adds an AI molecular modeling and predictive analytics platform to its drug discovery and development capabilities.
Shuttle Pharmaceuticals (NASDAQ: SHPH) entered a securities purchase agreement with a single investor to raise approximately $2.5 million in gross proceeds via the sale of a pre-funded warrant that can be exercised into up to 625,156 shares at an effective price of $4.00 per share. The price is described as above-the-market under Nasdaq rules. The Offering is expected to close on or about November 4, 2025, subject to customary closing conditions.
WestPark Capital is the exclusive placement agent. The company intends to use net proceeds for marketing, general corporate purposes and working capital and has agreed to file registration statement(s) to cover resale of shares issuable upon exercise of the pre-funded warrant.
Shuttle Pharmaceuticals (NASDAQ:SHPH) announced a definitive Letter of Intent dated October 22, 2025 to acquire substantially all assets and liabilities of Molecule.ai for approximately $10 million, payable in a mix of cash and common stock with timing and ratios tied to performance milestones. Molecule.ai provides an AI platform designed to reason with scientific data, predict molecular interactions, and iterate designs in real time. Shuttle positions the deal as a strategic shift from a chemistry-focused biotech to a hybrid platform company aiming to scale discovery through perpetual machine learning.